Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midazolam ED90 for Sedation in Upper Gastric Endoscopy
NCT03813043Unknown
- Sponsor
- King Fahad Specialist Hospital Dammam
- Start
- Feb 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
01
Overview
Open-label trial of midazolam in gastroesophageal reflux disease (GERD), sponsored by King Fahad Specialist Hospital Dammam. Primary endpoint: 90% Effective Dose at 10 months. Status: unknown.
02
Drugs
midazolam
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03813043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813043.